A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis
A randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and tolerability of LIV001 in patients with mild to moderate UC. Patients will receive LIV001 or placebo for 8 weeks. All patients will return to the site for a follow-up visit on week 12.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
15
Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska
Wroclaw, Poland
Number of subjects with adverse events (AEs)
Time frame: Baseline through Study Completion (Week 12).
Number of subjects with clinical laboratory abnormalities
Time frame: Baseline through Study Completion (Week 12).
Number of subjects with changes in the 12-lead electrocardiogram (ECG)
Time frame: Baseline through Study Completion (Week 12).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.